Veterinary Drug terms — page 17 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

Phosphonic acid derivatives Fosfomycin
Physcion 1,8-Dihydroxy-3-methoxy-6-methyl-9,10-anthracenedione; Physcion; 521-61-9; Physcione; Parietin; Rheochrysidin; Emodin 3-methyl ether; 1,8-Dihydroxy-3-methoxy-6-methylanthraquinone; 1,8-dihydroxy-3-methoxy-6-methylanthracene-9,10-dione; Emodin-3-methyl ether; NSC 251670; Emodin monomethyl ether; Parienin; UNII-H6PT94IV61; 1,8-Dihydroxy-3-methyl-6-methoxyanthraquinone; CCRIS 4399; 1,8-Dihydroxy-3-methoxy-6-methyl-9,10-anthracenedione; EINECS 208-315-7; Rheochrysidin (Physcione); NSC251670; BRN 1915778; 1,8-Dihydroxy-3-methyl-6-methoxy-9,10-anthraquinone; CHEMBL42624; H6PT94IV61; ANTHRAQUINONE, 1,8-DIHYDROXY-3-METHOXY-6-METHYL-; AK160252; Q-100587; 9,10-Anthracenedione, 1,8-dihydroxy-3-methoxy-6-methyl-; Methoxyemodin; fischione; Physcion,(S); Spectrum_001782; 9,10-dione; SpecPlus_000471; PHYSCION (SENNA); Rheochrysidin_120098; Spectrum2_000503; Spectrum3_001829; Spectrum4_000909; Spectrum5_001742; Rheochrysidin - Physcione; 1,8-Dihydroxy-3-methoxy-6-methyl-anthraquinone; BSPBio_003477; KBioGR_001378; KBioSS_002265; Physcion, analytical standard; DivK1c_006567; SCHEMBL486155; SPECTRUM1504070; SPBio_000425; MEGxm0_000018; CHEBI:38167; CTK8E3154; KBio1_001511; KBio2_002264; KBio2_004832; KBio2_007400; KBio3_002981; 1,8-dihydroxy-3-methoxy-6-methyl-anthracene-9,10-dione; DTXSID20200101; FFWOKTFYGVYKIR-UHFFFAOYSA-N; HMS3656I15; Physcion, >=98.0% (TLC); HY-N0108; KS-00000NK5; ZINC3978794; BDBM50005886; CCG-38713; CP-228; CP0083; MFCD00017374; s2395; AKOS015905689; AC-7979; KS-5385; LS-2148; NSC-251670; SDCCGMLS-0066772.P001; NCGC00096075-01; NCGC00096075-02; NCGC00096075-03; 9, 1,8-dihydroxy-3-methoxy-6-methyl-; AS-15488; NCI60_002011; P564; SC-46573; AX8008593; TR-018534; CS-0007795; FT-0657510; N1853; ST24048914; SW219324-1; 1,8-dihydroxy-3-methoxy-6-methylanthracene-; 1,8-dihydroxy-6-methoxy-3-methylanthraquinone; Anthraquinone,8-dihydroxy-3-methoxy-6-methyl-; C17045; 521P619; A828949; SR-05000002537; Q1668551; SR-05000002537-1; 8,9-dihydroxy-3-methyl-6-methoxy-1,10-anthraquinone; 8,9-dihydroxy-6-methyl-3-methoxy-1,10-anthraquinone; BRD-K67772619-001-03-6; 1,8-Dihydroxy-3-methoxy-6-methylanthra-9,10-quinone #; 7-methoxy-2-methyl-4,5-dihydroxyanthracene-9,10-dione; 3-methoxy-6-methyl-1,8-bis(oxidanyl)anthracene-9,10-dione; 9,10-Anthracenedione, 1,8-dihydroxy-3-methoxy-6-methyl- (9CI); Physcione; 4-08-00-03575 (Beilstein Handbook Reference)
Physostigmine (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol methylcarbamate (ester); Physostigmine; Antilirium
Piceatannol 4-[(1E)-2-(3,5-Dihydroxyphenyl)ethenyl]-1,2-benzenediol; piceatannol; 10083-24-6; 3-Hydroxyresveratol; 3,5,3',4'-Tetrahydroxystilbene; piceatanol; 3,3',4'5-Tetrahydroxystilbene; (E)-4-(3,5-dihydroxystyryl)benzene-1,2-diol; 3,3',4,5'-Tetrahydroxystilbene; 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol; UNII-6KS3LS0D4F; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol; C14H12O4; NSC 365798; NSC 622471; NSC-365798; 6KS3LS0D4F; CHEMBL69863; 3,3',4,5'-Stilbenetetrol; 4339-71-3; CHEBI:28814; NSC365798; NSC622471; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-; astringinin; 3,3',4,5'-Tetrahydroxy-trans-stilbene; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-, (E)-; 4-(3,5-dihydroxystyryl)benzene-1,2-diol; 3,3',4',5-tetrahydroxystilbene; Astringenin; 4-[(1E)-2-(3,5-Dihydroxyphenyl)ethenyl]-1,2-benzenediol; SMR001230734; SR-01000076056; MLS003171221; Astringinine; 1,2-Benzenediol, 4-[2-(3,5-dihydroxyphenyl)ethenyl]-, (E)-; CCRIS 9289; (E)-Piceatannol; 3,3',4,5'-tetrahydroxy stilbene; AK162486; Piceatannol, powder; BiomolKI_000023; BiomolKI2_000031; Lopac0_000915; SCHEMBL43541; BSPBio_001120; MLS002153321; MLS006010974; trans-3,3′ ,4,5′ -Tetrahydroxystilbene; BIDD:ER0001; SCHEMBL505561; BMK1-C11; cid_667639; MEGxp0_000245; DTXSID6040587; REGID_for_CID_667639; Stilbene-3,3',4,5'-tetrol; CHEBI:92460; ZINC14036; CDRPUGZCRXZLFL-OWOJBTEDSA-N; HMS1362H21; HMS1792H21; HMS1990H21; HMS2236B03; HMS3262H12; HMS3403H21; HMS3412J21; HMS3676J21; ML027; Tox21_500915; 3,3'',4,5''-tetrahydroxystilbene; BDBM50045936; BS0146; GP2416; LMPK13090006; MFCD00221715; s3026; 3,4,3'',5''-tetrahydroxystillbene; AKOS015914951; AC-5281; CCG-100627; CS-5657; DB08399; FC-5001; LP00915; NSC-622471; RTX-010361; SDCCGSBI-0050890.P002; IDI1_002155; SMP2_000263; trans-3,3',4,5'-Tetrahydroxystilbene; 3,4,3',5'-tetrahydroxy-trans-stilbene; NCGC00094226-01; NCGC00094226-02; NCGC00094226-03; NCGC00094226-04; NCGC00094226-05; NCGC00094226-06; NCGC00094226-07; NCGC00261600-01; AS-18099; HY-13518; SC-28783; trans-3,3'',4,5''-tetrahydroxystilbene; 3,4,3'',5''-tetrahydroxy-trans-stilbene; AB0137762; AX8161462; LS-146872; LS-171757; EU-0100915; N2031; P1928; ST24035059; ST50825907; SW219501-1; W2087; A12162; C05901; K00089; P 0453; 339P713; A800279; 1, 4-[2-(3,5-dihydroxyphenyl)ethenyl]-, (E)-; CU-00000000400-1; J-000228; Q7190608; SR-01000076056-1; SR-01000076056-6; SR-01000076056-9; BRD-K91509126-001-04-6; BRD-K91509126-001-05-3; (E)-4-[2-(3,5Dihydroxyphenyl)ethenyl]1,2-benzenediol; F13BE9BB-B7D7-4D40-B31A-C15B953E033D; (E)-4-[2-(3,5-Dihydroxyphenyl)ethenyl]1,2-benzenediol; 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol; 4-[(1E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol; 5-[(E)-2-(3,4-Dihydroxyphenyl)vinyl]benzene-1,3-diol; 4-[(E)-2-[3,5-bis(oxidanyl)phenyl]ethenyl]benzene-1,2-diol; 4-[2-(3,5-dihydroxyphenyl)-(E)-1-ethenyl]-1,2-benzenediol; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol(Piceatannol); 4-[2-(3,5-dihydroxyphenyl)-(E)-1-ethenyl]-1,2-benzenediol(Piceatannol); 3,3',4,5'-Tetrahydroxystilbene; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-, (E)-
Picric acid 2,4,6-Trinitrophenol; PICRIC ACID; 2,4,6-Trinitrophenol; Trinitrophenol; 88-89-1; Carbazotic acid; Picronitric acid; Melinite; Acide picrique; Phenol trinitrate; Picral; Nitroxanthic acid; Pikrinsaeure; Phenol, 2,4,6-trinitro-; Pikrinezuur; Acido picrico; Pikrynowy kwas; 2-Hydroxy-1,3,5-trinitrobenzene; Phenoltrinitrate; Kyselina pikrova; Acidum picrinicum; 1,3,5-Trinitrophenol; Pikrinezuur [Dutch]; Pikrinsaeure [German]; C.I. 10305; 2,4,6-Trinitrofenol; 2,4,6-Trinitrofenolo; 2,4,6-Trinitrophenyl; Acide picrique [French]; Acido picrico [Italian]; Pikrynowy kwas [Polish]; Kyselina pikrova [Czech]; UNII-A49OS0F91S; NSC 36947; CCRIS 3106; 2,4,6-Trinitrofenol [Dutch]; CI 10305; HSDB 2040; 2,4,6-Trinitrofenolo [Italian]; EINECS 201-865-9; NA1344; UN0154; UN1344; picric; AI3-15403; A49OS0F91S; CHEBI:46149; Picric acid, dry; Picric acid, wet; OXNIZHLAWKMVMX-UHFFFAOYSA-N; 2,6-Trinitrofenol; Pertite; Picric acid (dry); Picric acid (wet); 1,5-Trinitrophenol; 2,6-Trinitrofenolo; 2,6-Trinitrophenol; Phenol,4,6-trinitro-; WLN: WNR BQ CNW ENW; 2-Hydroxy-1,5-trinitrobenzene; Picric acid, dry or wetted with < 30% water, by mass; Trinitrophenol, dry or wetted with < 30% water, by mass; Picricum acidum; 2,4,6-Trinitrophenol (Picric Acid); Trinitrophenol [NF]; Reflorit; Hager's reagent; Picric acid solution; Picric acid, p.a.; Lyddite (Salt/Mix); Ecrasite (Salt/Mix); Schimose (Salt/Mix); SCHEMBL8745; NA 1344 (Salt/Mix); UN 1344 (Salt/Mix); CHEMBL108541; DTXSID4025909; SCHEMBL14419782; BDBM34612; cid_3241713; CTK3E8533; NSC36947; NSC56147; ZINC1883067; 3-Hydroxy-2,4,6-trinitrobenzenide; BBL020094; NSC-36947; NSC-56147; STL199171; ZINC71129432; AKOS008966816; API0003844; DB03651; LS-1888; MCULE-8917344355; RTR-027961; UN 0154; Picric acid, wet, with not <10% water; AB1002452; BC4124115; DB-057108; Picric acid, moistened with water, >=98%; TR-027961; FT-0609916; H2982; Picric acid, SAJ special grade, >=99.5%; 2-methylbenzo[g][1,3]benzoxazole; picric acid; 1769-EP2269978A2; 1769-EP2269985A2; 1769-EP2269990A1; 1769-EP2269991A2; 1769-EP2272832A1; 1769-EP2277865A1; 1769-EP2277876A1; 1769-EP2280006A1; 1769-EP2280010A2; 1769-EP2281813A1; 1769-EP2281815A1; 1769-EP2284150A2; 1769-EP2284151A2; 1769-EP2284152A2; 1769-EP2284153A2; 1769-EP2284155A2; 1769-EP2284156A2; 1769-EP2284164A2; 1769-EP2287140A2; 1769-EP2287148A2; 1769-EP2287150A2; 1769-EP2289886A1; 1769-EP2289894A2; 1769-EP2292590A2; 1769-EP2292614A1; 1769-EP2295412A1; 1769-EP2295413A1; 1769-EP2295419A2; 1769-EP2295423A1; 1769-EP2298731A1; 1769-EP2298742A1; 1769-EP2298743A1; 1769-EP2301534A1; 1769-EP2301912A2; 1769-EP2301916A2; 1769-EP2301922A1; 1769-EP2301933A1; 1769-EP2305637A2; 1769-EP2305640A2; 1769-EP2305648A1; 1769-EP2305695A2; 1769-EP2305696A2; 1769-EP2305697A2; 1769-EP2305698A2; 1769-EP2308833A2; 1769-EP2308861A1; 1769-EP2308875A1; 1769-EP2311451A1; 1769-EP2311796A1; 1769-EP2311797A1; 1769-EP2311798A1; 1769-EP2311799A1; 1769-EP2311808A1; 1769-EP2311827A1; 1769-EP2311829A1; 1769-EP2311837A1; 1769-EP2314575A1; 1769-EP2316450A1; 1769-EP2316459A1; 1769-EP2316834A1; 1769-EP2316836A1; 1769-EP2374454A1; 42218-EP2298742A1; 42218-EP2298766A1; 42218-EP2298770A1; 42218-EP2311808A1; 42218-EP2311829A1; 50414-EP2295421A1; 50414-EP2311809A1; 50414-EP2371810A1; 50414-EP2371812A1; Picric acid solution, 0.9-1.1% (alkalimetric); Picric acid solution, 1.3% in H2O (saturated); A842990; C-42378; Q189298; SR-01000944524; 1-methyl-3,4-dihydro-2H-beta-carboline; picric acid; 2,4,6-Trinitrophenol 10 microg/mL in Acetonitrile; SR-01000944524-1; 2,4,6-Trinitrophenol 100 microg/mL in Acetonitrile; Trinitrophenol, wetted with not <30% water, by mass; 2-methylbenzo[g][1,3]benzoxazole; 2,4,6-trinitrophenol; F0001-2190; Picric acid solution, ~1.3% in H2O, solution (saturated aqueous); Picric acid, wet, with not <10% water [NA1344] [Flammable solid]; Picric acid, wet, with not <10% water [NA1344] [Flammable solid]; Trinitrophenol or picric acid, dry or wetted with <30% water, by mass; Picric acid solution, 100 mug/mL in acetonitrile, PESTANAL(R), analytical standard; Picric acid, purum, moistened with >=40% water, >=98.0% (calc. on dry substance, T); Trinitrophenol, wetted with not <30% water, by mass [UN1344] [Flammable solid]; Trinitrophenol, wetted with not <30% water, by mass [UN1344] [Flammable solid]; InChI=1/C6H3N3O7/c10-6-4(8(13)14)1-3(7(11)12)2-5(6)9(15)16/h1-2,10; Trinitrophenol or picric acid, dry or wetted with <30% water, by mass [UN0154] [Explosive 1.1D]; Trinitrophenol or picric acid, dry or wetted with <30% water, by mass [UN0154] [Explosive 1.1D]; Picric acid; C.I. 10305
Pimelic acid Heptanedioic acid; Pimelic acid; 4-02-00-02003 (Beilstein Handbook Reference)
Pimozide 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; pimozide; 2062-78-4; Orap; Opiran; Pimozidum; Pimozidum [INN-Latin]; McN-JR-6238; R-6238; Primozida [INN-Spanish]; R 6238; UNII-1HIZ4DL86F; NSC 170984; McN-JR 6238; CCRIS 9172; C28H29F2N3O; EINECS 218-171-7; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; BRN 0729089; 1HIZ4DL86F; CHEMBL1423; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; MLS000028410; MLS002702058; CHEBI:8212; NSC170984; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 2H-Benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro-; 2H-Benzimidazol-2-one, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-; NSC-170984; NCGC00015802-08; NCGC00015802-18; Primozida; SMR000058385; CAS-2062-78-4; DSSTox_CID_3474; DSSTox_RID_77042; DSSTox_GSID_23474; pimozida; Primozide; Pimozida [INN-Spanish]; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 2-Benzimidazolinone, 1-[1-[4,4-bis(p-fluorophenyl)butyl]-4-piperidyl]-; Orap (TN); Pimozide [USAN:INN:BAN:JAN]; SR-01000075392; 2-Benzimidazolinone, 1-(1-(4,4-bis(p-fluorophenyl)butyl)-4-piperidyl)-; Prestwick_395; Pimozide [USAN:USP:INN:BAN:JAN]; Spectrum_000445; Tocris-0937; Opera_ID_1580; Prestwick0_000308; Prestwick1_000308; Prestwick2_000308; Prestwick3_000308; Spectrum2_001026; Spectrum3_001451; Spectrum4_000420; Spectrum5_001308; Lopac-P-1793; GTPL90; NCIMech_000356; P 1793; Lopac0_000946; SCHEMBL41584; BSPBio_000276; BSPBio_001439; BSPBio_002941; KBioGR_000720; KBioSS_000925; 5-24-02-00367 (Beilstein Handbook Reference); MLS001077311; BIDD:GT0435; DivK1c_000386; SPECTRUM1501134; Pimozide (JP17/USP/INN); SPBio_001211; SPBio_002495; BPBio1_000304; SCHEMBL7519553; DTXSID8023474; BCBcMAP01_000043; CTK8G2428; HMS501D08; KBio1_000386; KBio2_000925; KBio2_003493; KBio2_006061; KBio3_002441; AOB5780; NINDS_000386; YVUQSNJEYSNKRX-UHFFFAOYSA-N; HMS1568N18; HMS1791H21; HMS1921H19; HMS1989H21; HMS2089C11; HMS2092F09; HMS2095N18; HMS2231P23; HMS3262N14; HMS3267E19; HMS3370N13; HMS3402H21; HMS3411J16; HMS3675J16; HMS3712N18; Pharmakon1600-01501134; KS-000018AL; ZINC4175630; Tox21_110224; Tox21_301586; Tox21_500946; BDBM50334150; BG0381; CCG-35918; CCG-36461; CCG-39728; MFCD00055081; NSC757854; 3-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidyl]-1H-benzimidazol-2-one; AKOS024458706; Tox21_110224_1; API0003851; DB01100; LP00946; NSC-757854; SDCCGSBI-0050920.P004; IDI1_000386; SMP1_000241; NCGC00015802-01; NCGC00015802-02; NCGC00015802-03; NCGC00015802-04; NCGC00015802-05; NCGC00015802-06; NCGC00015802-07; NCGC00015802-09; NCGC00015802-10; NCGC00015802-11; NCGC00015802-12; NCGC00015802-13; NCGC00015802-14; NCGC00015802-15; NCGC00015802-16; NCGC00015802-26; NCGC00016601-01; NCGC00022282-03; NCGC00024888-01; NCGC00024888-02; NCGC00024888-03; NCGC00024888-04; NCGC00024888-05; NCGC00024888-06; NCGC00024888-07; NCGC00255294-01; NCGC00261631-01; AS-13916; HY-12987; LS-33236; M828; SBI-0050920.P003; AB00052215; CS-0012921; EU-0100946; FT-0673903; R-623; SW196639-3; C07566; D00560; AB00052215-06; AB00052215_07; AB00052215_08; 062P784; 117210-EP2272537A2; 117210-EP2275420A1; 117210-EP2295061A1; 117210-EP2298776A1; L000494; Q144085; WLN: T56 BMVNJ D- DT6NTJ A3YR DF&R DF; J-013477; SR-01000075392-1; SR-01000075392-3; SR-01000075392-4; SR-01000075392-6; BRD-K01292756-001-06-0; BRD-K01292756-001-13-6; Pimozide, European Pharmacopoeia (EP) Reference Standard; Z241910386; 2-Benzimidazolinone,4-bis(p-fluorophenyl)butyl]-4-piperidyl]-; N-benzyl-N-(3-isobutoxy-2-(pyrrolidin-1-yl)propyl)benzenamine; Pimozide, United States Pharmacopeia (USP) Reference Standard; 1-[1-[4,4-Bis(p-flurophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-(1-(4,4-bis(4-fluorophenyl)butyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one; 1-(1-(4,4-bis(4-fluorophenyl)butyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 1-{1-[4,4-bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one; 2H-Benzimidazol-2-one,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-; 1-{1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one(Pimozide); PIMOZIDE1-{1-[4,4-BIS-(4-FLUORO-PHENYL)-BUTYL]-PIPERIDIN-4-YL}-1,3-DIHYDRO-BENZOIMIDAZOL-2-ONE; Pimozide; R 6238
Pindolol 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; pindolol; Visken; 13523-86-9; Prinodolol; Betapindol; Carvisken; Durapindol; Pinbetol; Calvisken; Decreten; Pectobloc; Pynastin; Blocklin L; Pindololum; LB-46; Glauco-visken; Glauco-Viskin; Blockin L; LB 46; (+-)-Pindolol; Blocklin-L; Pindololum [INN-Latin]; 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole; 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole; CCRIS 9215; HSDB 6539; 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol; EINECS 236-867-9; EINECS 244-623-8; 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol; 2-Propanol, 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]-; 2-Propanol, 1-(4-indolyloxy)-3-(isopropylamino)-; BRN 1536506; CHEBI:8214; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; 2-Propanol, 1-(1H-indol-4-yloxy)-3-((1-methylethyl)amino)-; JZQKKSLKJUAGIC-UHFFFAOYSA-N; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; NCGC00015786-11; (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol; Prindolol; DSSTox_CID_3476; DL-Pindolol; DSSTox_RID_77043; DSSTox_GSID_23476; 1-((1H-indol-4-yl)oxy)-3-(isopropylamino)propan-2-ol; 1-[1H-INDOL-4-YLOXY]-3-[ISOPROPYLAMINO]-2-PROPANOL; 2-Propanol, 1-(1H-indol-4-yloxy)-3-(1-methylethyl)amino-; 2-Propanol, 1-(indol-4-yloxy)-3-(isopropylamino)-, (+-)-; Blocklin; Carvisken (TN); SMR000059120; Blocklin-L (TN); Visken (TN); Pindolol [USAN:INN:BAN:JAN]; SR-01000000027; DL-LB 46; Prestwick_397; CAS-13523-86-9; Pindolol [USAN:USP:INN:BAN:JAN]; Spectrum_001109; (.+/-.)-Pindolol; Prestwick0_000090; Prestwick1_000090; Prestwick2_000090; Prestwick3_000090; Spectrum2_001285; Spectrum3_000547; Spectrum4_000479; Spectrum5_001266; (R,S)-PINDOLOL; CHEMBL500; GTPL91; PINDOLOL,(-); P 0778; P-6820; SCHEMBL5219; Lopac0_000955; Oprea1_770884; BSPBio_000020; BSPBio_002193; KBioGR_000958; KBioSS_001589; 5-21-03-00017 (Beilstein Handbook Reference); DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole; MLS000069496; MLS002548891; DivK1c_000837; SPECTRUM1500488; Pindolol (JP17/USP/INN); SPBio_001289; SPBio_001959; BPBio1_000022; DTXSID8023476; CTK8G2432; HMS502J19; KBio1_000837; KBio2_001589; KBio2_004157; KBio2_006725; KBio3_001693; NINDS_000837; 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; HMS1568A22; HMS1920H16; HMS2089I21; HMS2091P20; HMS2095A22; HMS3259I07; HMS3262P12; HMS3267K17; HMS3369E14; HMS3414J03; HMS3678H21; HMS3712A22; HMS3742C07; Pharmakon1600-01500488; HY-B0982; Pindolol, >=98% (TLC), powder; Tox21_110221; Tox21_500955; BDBM50019443; CCG-39223; MFCD00010530; NSC757276; PDSP1_000771; PDSP1_000772; PDSP2_000759; PDSP2_000760; AKOS015969756; Tox21_110221_1; CS-4473; DB00960; LP00955; MCULE-7764948919; NC00467; NSC-757276; SDCCGSBI-0050929.P005; IDI1_000837; NCGC00015786-06; NCGC00015786-07; NCGC00015786-08; NCGC00015786-09; NCGC00015786-10; NCGC00015786-13; NCGC00015786-14; NCGC00015786-16; NCGC00015786-20; NCGC00024925-03; NCGC00024925-04; NCGC00024925-05; NCGC00024925-06; NCGC00024925-07; NCGC00261640-01; CPD000059120; SAM002264631; SC-25688; SBI-0050929.P004; LS-122385; AB00052072; EU-0100955; FT-0630406; ST50319990; SW196641-3; Z3376; C07445; D00513; AB00052072-11; AB00052072_12; AB00052072_13; 1-(4-Indolyloxy)-3-(isopropylamino)-2-propanol; 523P869; L000006; Q418101; 3-indol-4-yloxy-1-[(methylethyl)amino]propan-2-ol; SR-01000000027-2; SR-01000000027-4; SR-01000000027-5; SR-01000000027-7; 1-(1H-Indol-4-yloxy)-3-isopropylamino-propan-2-ol; BRD-A97701745-001-05-3; BRD-A97701745-001-09-5; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol #; Pindolol, European Pharmacopoeia (EP) Reference Standard; (+/-)-1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(1H-Indol-4-yloxy)-3-isopropylamino-propan-2-ol(pindolol); 1-[(1H-Indol-4-yl)oxy]-3-[(propan-2-yl)amino]propan-2-ol; Pindolol, United States Pharmacopeia (USP) Reference Standard; 1-(1H-Indol-4-yloxy)-3-isopropylamino-propan-2-ol((-)-Pindolol); Pindolol; 5-21-03-00017 (Beilstein Handbook Reference)
Piracetam 2-Oxo-1-pyrrolidineacetamide; piracetam; 7491-74-9; 2-(2-oxopyrrolidin-1-yl)acetamide; Nootropil; 2-Oxo-1-pyrrolidineacetamide; Nootropyl; Pyracetam; 1-Pyrrolidineacetamide, 2-oxo-; Normabrain; Gabacet; Pyramem; CiclofaliGenogris; Pirazetam; Pirroxil; Euvifor; Nootron; 2-Pyrrolidinoneacetamide; 2-Oxo-pyrrolidine acetamide; 2-Pyrrolidoneacetamide; UCB 6215; Naofukang [Chinese]; 1-Acetamido-2-pyrrolidinone; 2-(2-oxo-pyrrolidin-1-yl)acetamide; 2-Oxo-pyrrolidin-1-ylacetamide; 2-Ketopyrrolidine-1-ylacetamide; Cl-871; Piracetamum [INN-Latin]; UNII-ZH516LNZ10; KT-801; MLS000069719; 2-(2-Oxo-1-pyrrolidinyl)acetamide; EINECS 231-312-7; BRN 1526393; SMR000058196; 2-(2-Oxopyrrolidino)acetamide; ZH516LNZ10; 2-(2-ketopyrrolidino)acetamide; GMZVRMREEHBGGF-UHFFFAOYSA-N; NCGC00015821-02; CAS-7491-74-9; 2-(2-oxidanylidenepyrrolidin-1-yl)ethanamide; DSSTox_CID_24491; DSSTox_RID_80267; DSSTox_GSID_44491; 2-(2-oxopyrrolidinyl)acetamide; Cerebroforte; Piracetamum; Avigilen; Breinox; Naofukang; Nootrop; Axonyl; Geram; SR-01000076071; 2-Pyrrolidone-N-Acetamide; Encetrop; Norzetam; Piracetam [USAN:BAN:INN]; Piracetam [USAN:INN:BAN]; HSDB 7529; Piracetam,(S); UCB-6215; Prestwick_870; Myocalm (TN); Spectrum_001421; Opera_ID_1766; Prestwick0_000537; Prestwick1_000537; Prestwick2_000537; Prestwick3_000537; Spectrum2_001074; Spectrum3_001523; Spectrum4_000742; Spectrum5_001037; Lopac-P-5295; cid_4843; Lopac0_000949; Oprea1_512927; SCHEMBL20172; BSPBio_000553; BSPBio_002906; KBioGR_001064; KBioSS_001901; 5-21-06-00360 (Beilstein Handbook Reference); Piracetam (JAN/USAN/INN); CHEMBL36715; DivK1c_000259; SPECTRUM1502195; SPBio_001088; SPBio_002474; BPBio1_000609; GTPL4288; DTXSID5044491; BDBM62877; CHEBI:32010; Cl-781; CTK7D3269; HMS500M21; KBio1_000259; KBio2_001901; KBio2_004469; KBio2_007037; KBio3_002406; NINDS_000259; HMS1569L15; HMS1921L12; HMS2092D18; HMS2096L15; HMS2230B24; HMS3262N20; HMS3371G01; HMS3657A05; HMS3713L15; Pharmakon1600-01502195; BCP28414; HY-B0585; KS-00000K5B; ZINC3812874; Tox21_110229; Tox21_301990; Tox21_500949; BBL028161; CCG-39282; MFCD00079246; NSC758191; s3070; SBB086233; STK535612; 2 - Oxo - 1 - pyrrolidineacetamide; AKOS001038683; Tox21_110229_1; 2-(2-Oxo-1-pyrrolidinyl)acetamide #; CS-2774; DB09210; LP00949; MCULE-7645397226; NSC-758191; SDCCGSBI-0050923.P004; IDI1_000259; NCGC00015821-01; NCGC00015821-03; NCGC00015821-04; NCGC00015821-05; NCGC00015821-06; NCGC00015821-07; NCGC00015821-08; NCGC00015821-10; NCGC00094253-01; NCGC00094253-02; NCGC00094253-03; NCGC00094253-04; NCGC00255727-01; NCGC00261634-01; AK326212; AS-13920; K282; SC-78454; SBI-0050923.P003; AB0014139; AB1009436; DB-019407; LS-137082; TX-017921; AB00052287; EU-0100949; FT-0636504; ST50182453; SW196995-3; Piracetam, VETRANAL(TM), analytical standard; D01914; M-3297; P 5295; 96625-EP2287163A1; 96625-EP2305678A1; AB00052287_12; A838261; AE-641/30117005; Q410069; SR-01000076071-1; SR-01000076071-4; SR-01000076071-6; W-104408; BRD-K19456237-001-22-7; Z56865289; Piracetam, European Pharmacopoeia (EP) Reference Standard; 2-(2-Oxopyrrolidino)acetamide; 2-Oxo-1-pyrrolidineacetamide; Piracetam; 5-21-06-00360 (Beilstein Handbook Reference)
Pirenzepine 5,11-Dihydro-11-[2-(4-methyl-1-piperazinyl)acetyl]-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one; Pirenzepine; BRN 0628987
Piromidic acid 8-Ethyl-5,8-dihydro-5-oxo-2-(1-pyrrolidinyl)-pyrido[2,3-d]pyrimidine-6-carboxylic acid; Piromidic acid; Acide piromidique [INN-French]
Piroxicam
Pleuromutilins Retapamulin; Tiamulin; Valnemulin
Podofilox (5R,5aR,8aR,9R)-5,8,8a,9-Tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one; podophyllotoxin; Podofilox; 518-28-5; Condylox; Condyline; Wartec; (-)-Podophyllotoxin; Podophyllinic acid lactone; Podophyllotoxin 7; Warticon; Podophyllum; Podofilox [USAN]; CCRIS 565; UNII-L36H50F353; HSDB 7238; Podophyllotoxin, 95%; NSC24818; CHEMBL61; EINECS 208-250-4; NSC 24818; AI3-50456; MLS000069495; (5R,5aR,8aR,9R)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one; CHEBI:50305; 4354-76-1; Podofilox (USAN); NSC-24818; L36H50F353; (10R,11R,15R,16R)-16-hydroxy-10-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R-(5alpha,5abeta,8aalpha,9alpha))-; NCGC00022001-05; Podofilm; SMR000059121; EN300-52746; DSSTox_CID_25645; DSSTox_RID_81023; DSSTox_GSID_45645; (5R,5aR,8aR,9R)-5,8,8a,9-Tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one; (5R,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[5,6-f][1,3]benzodioxol-8-one; Podocon-25; Podophilox; (5R,9R,5aR,8aR)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,9,5a,8a-pentahydro-2H -isobenzofurano[5',6'-2,1]benzo[4,5-d]1,3-dioxolan-6-one; 1,3,3a,4,9,9a-Hexahydro-9-hydroxy-6,7-(methylenedioxy)-4-(3',4',5'-trimethoxyphenyl)benz(f)isobenzofuran-3-one; SR-05000001749; MLS002702981; CPH86; PodofilliPodophylotoxin; Mayapple isolate; Condylox (TN); (5R,5aR,8aR,9R)-5,8,8a,9-Tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one; CAS-518-28-5; Podophyllotoxin,(S); Prestwick_1018; Podofillina [Italian]; Podophyllotoxin (BAN); PubChem20017; Spectrum_000199; Opera_ID_1397; Prestwick0_000782; Prestwick1_000782; Prestwick2_000782; Prestwick3_000782; Spectrum2_000878; Spectrum4_000592; Spectrum5_001368; UPCMLD-DP035; SCHEMBL42243; BSPBio_000884; BSPBio_002352; KBioGR_001084; KBioSS_000679; MLS001148204; MLS002172467; MLS006010754; MLS006011412; BIDD:GT0123; DivK1c_000292; UNII-16902YVY2B; SPBio_000955; SPBio_002823; BPBio1_000974; CCRIS 4391; DTXSID3045645; UPCMLD-DP035:001; UPCMLD-DP035:002; BCBcMAP01_000165; CTK6J6283; HMS500O14; KBio1_000292; KBio2_000679; KBio2_003247; KBio2_005815; NINDS_000292; YJGVMLPVUAXIQN-XVVDYKMHSA-N; 16902YVY2B; HMS1570M06; HMS2093P16; HMS2097M06; HMS2235A23; HMS3259J19; HMS3714M06; Pharmakon1600-02300332; 9-Hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5ah)-one; ALBB-020906; BB_NC-01063; BCP24085; Podophyllotoxin, analytical standard; ZINC3861806; EINECS 232-546-2; Tox21_110874; Tox21_202922; B18-5C; BBL033695; BDBM50035218; CCG-39894; CP0089; MFCD00075290; NSC759591; STK801918; AKOS000265559; Tox21_110874_1; AC-1656; CS-1185; DB01179; KS-1281; MCULE-9617461427; NC00675; ND-1185; NSC-759591; SDCCGMLS-0066888.P001; IDI1_000292; SMP1_000243; NCGC00022001-03; NCGC00022001-07; NCGC00022001-08; NCGC00022001-09; NCGC00022001-10; NCGC00022001-11; NCGC00022001-13; NCGC00022001-14; NCGC00260468-01; CC-33854; CPD000059121; HY-15552; LS-70859; NCI60_001981; RD4-6269; SAM002548978; SC-47262; SC-77494; ST066914; AB0012227; FT-0603436; ST24048942; C10874; D05529; P-6980; W-5067; 70339-EP2305243A1; 70339-EP2308833A2; 518P285; A828801; C-21968; Q421193; SR-01000003030; SR-01000003030-3; SR-05000001749-1; SR-05000001749-2; BRD-K47869605-001-05-6; BRD-K47869605-001-18-9; Z1258578359; (10R,11R,15R,16R)-16-hydroxy-10-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0?,?.0??,??]hexadeca-1(9),2,7-trien-12-one; (5R,5aR,8aR,9R)-5,8,8a,9-Tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-furo(3',4':6,7)naphtho[2,3-d]-1,3-dioxol-6(5aH)-one; (5R,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-8-one; (5R,5aR,8aR,9R)-5-oxidanyl-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one; (5R,5aR,8aR,9R)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one; (5R,5aR,8aR,9R)-9-Hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydro-2H-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one; 5,8,8a,9-Tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, [5R-(5.alpha.,5a.beta.,8a.alpha.,9.alpha.)]; furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R,5aR,8aR,9R)-; Furo[3',7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, [5R-(5.alpha.,5a.beta.,8a.alpha.,9.alpha.)]-; Naphtho[2,3-dioxole-6-carboxylic acid, 5,6,7,8-tetrahydro-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl-, .gamma.-lactone; Podofilox [USAN]; AI3-50456
Podophyllum resin Podophyllin; PODOPHYLLIN; Podophyllum resin; 9000-55-9; Podophylline; CTK8G2489; DB09094; Q22075831; CCRIS 4391
Poly (hexamethylene biguanide) hydrochloride Poly(iminocarbonimidoyliminocarbonimidoylimino-1,6-hexanediylhydrochloride); Polymeric biguanide polihexanide; Caswell No. 676
Polymyxin B Aerosporin
Polymyxins Colistin; Polymyxin B
Polypeptide antibiotics Bacitracin
Potassium citrate anhydrous 2-Hydroxy-1,2,3-propanetricarboxylic acid, Tripotassium salt; Potassium citrate anhydrous; CCRIS 6566
Potassium sorbate (2E,4E)-2,4-Hexadienoic acid, Potassium salt (1:1); Potassium sorbate [NF]; E 202
Practolol N-[4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]acetamide; practolol; 6673-35-4; Dalzic; Eraldin; Teranol; Practololum; Praktololu; Practololo [DCIT]; Praktololu [Polish]; rac Practolol; ICI 50172; Practololum [INN-Latin]; AY 21011; (+/-)-Practolol; 1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol; ICI-50172; CCRIS 1089; N-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; 4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide; N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide; Eralzdin Practolol; N-[4-[2-HYDROXY-3-[(1-METHYLETHYL)AMINO]PROPOXY]PHENYL]ACETAMIDE; EINECS 229-712-1; N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; CHEMBL6995; CHEBI:258351; N-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; Acetamide, N-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-; (+-)-Practolol; NCGC00024810-02; AY-21011; N-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; N-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide; Practololo; dl-Practolol; DSSTox_CID_1179; N-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; DSSTox_RID_75993; DSSTox_GSID_21179; 4'-[2-Hydroxy-3-(Isopropylamino)propoxy]acetanilide; Acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)-; Acetanilide, 4'-[2-hydroxy-3-(isopropylamino)propoxy]-; Prestwick_742; Acetamide, N-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-; Acetamide,N-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-; Spectrum_001454; Practolol [USAN:BAN:INN]; SR-01000597449; Practalol; Practolol [USAN:INN:BAN]; Practolol,(+); Practolol,(-); CAS-6673-35-4; Practolol (USAN); Prestwick0_000332; Prestwick1_000332; Prestwick2_000332; Prestwick3_000332; Spectrum2_001572; Spectrum4_000859; Spectrum5_001123; Oprea1_095524; SCHEMBL39925; BSPBio_000363; GTPL555; KBioGR_001497; KBioSS_001934; MLS002153779; DivK1c_000901; SPBio_001504; SPBio_002284; BPBio1_000401; DTXSID0021179; Practolol, >=95% (HPLC); BDBM25749; CTK5C5115; HMS502N03; KBio1_000901; KBio2_001934; KBio2_004502; KBio2_007070; DURULFYMVIFBIR-UHFFFAOYSA-N; NINDS_000901; HMS1569C05; HMS2089I09; HMS2096C05; HMS2233K23; HMS3374G04; HMS3713C05; Tox21_110928; CCG-39350; STL489279; AKOS002685374; AKOS016054902; Tox21_110928_1; DB01297; MCULE-7992924679; NE25450; IDI1_000901; NCGC00024810-03; NCGC00024810-04; NCGC00024810-07; LS-10763; SMR001233163; I.C.I. 50,172; SBI-0051937.P002; AY-21,011; AB00052459; FT-0673986; Z3381; EN300-72170; C11696; D05587; L000491; Q7237376; SR-01000597449-1; SR-01000597449-2; SR-01000597449-4; 4-[2-Hydroxy-3-(isopropylamino)propoxy]-acetanilide; BRD-A41304429-001-04-9; BRD-A41304429-001-12-2; Z274728816; N-(4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl)acetamide #; [3-(4-Acetylamino-phenoxy)-2-hydroxy-propyl]-isopropyl-ammonium; Practolol; 1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol
Pralidoximum 2-[(Hydroxyimino)methyl]-1-methylpyridinium; pralidoxime; Duodote; Atnaa; 6735-59-7; CHEBI:8354; C7H9N2O; Spectrum_001144; 2-[(HYDROXYIMINO)METHYL]-1-METHYLPYRIDINIUM; Prestwick0_000943; Prestwick1_000943; Spectrum2_000921; Spectrum3_001498; Spectrum4_000323; pralidoxime, 14C-labeled; CHEMBL1420; KBioGR_000665; KBioSS_001624; DivK1c_000770; SPBio_000822; SPBio_003065; N-methyl-pyridinium-2-aldoxime; GTPL4652; CTK5C6079; KBio1_000770; KBio2_001624; KBio2_004192; KBio2_006760; KBio3_002615; NINDS_000770; LS-175862; Pyridinium,2-[(hydroxyimino)methyl]-1-methyl-; 2-[(E)-(Hydroxyimino)methyl]-1-methylpyridin-1-ium; [(1-methyl-1,2-dihydropyridin-2-ylidene)methyl](oxo)azanium; Pralidoxime; EINECS 229-787-0
Prazepam prazepam; Demetrin; Lysanxia; Centrax; Trepidan; Verstran; 2955-38-6; Prazepamum [INN-Latin]; K-373; W 4020; UNII-Q30VCC064M; NSC 277179; 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-; EINECS 220-975-8; 7-Chloro-1-cyclopropylmethyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one; BRN 0895797; C19H17ClN2O; 7-Chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; CHEBI:8362; Q30VCC064M; DEA No. 2764; Prazene; Sedapran; MWQCHHACWWAQLJ-UHFFFAOYSA-N; W-4020; 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one; NCGC00168256-01; Prazeene; Prazepamum; Settima; DSSTox_CID_1181; 2H-1,4-BENZODIAZEPIN-2-ONE, 1,3-DIHYDRO-7-CHLORO-1-(CYCLOPROPYLMETHYL)-5-PHENYL-; 7-Chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; DSSTox_RID_75994; DSSTox_GSID_21181; 7-chloro-1-(cyclopropylmethyl)-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one; Centrax (TN); CAS-2955-38-6; Prazepam [USAN:INN:BAN:JAN]; Prazepam [USAN:USP:INN:BAN:JAN]; CHEMBL969; SCHEMBL78272; MLS003899231; GTPL7275; Prazepam (JP17/USAN/INN); ZINC1971; DTXSID4021181; CTK6H1723; Prazepam 0.1 mg/ml in Methanol; Prazepam 1.0 mg/ml in Methanol; Tox21_112615; Tox21_200076; NSC277179; 1-(cyclopropylmethyl)-5-phenyl-7-chloro-1h-1,4-benzodiazepin-2(3h)-one; DB01588; LS-7667; NSC-277179; NCGC00168256-02; NCGC00257630-01; CC-33902; SMR000058725; DB-047601; FT-0603623; C07366; D00470; C-19823; WLN: T67 GNV JN IHJ CG KR& G1- AL3TJ; Q2149443; 7-Chloro-1-(cyclopropylmethyl)-1,4-benzodiazepin-2-one; Prazepam, European Pharmacopoeia (EP) Reference Standard; 2H-1, 1,3-dihydro-7-chloro-1-(cyclopropylmethyl)-5-phenyl-; 2H-1, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-; Prazepam, United States Pharmacopeia (USP) Reference Standard; 7-Chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one #; Prazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Prazepam; K-373
Prazosin [4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-furanylmethanone; Prazosin; 5-25-13-00365 (Beilstein Handbook Reference)
Prednimustine PREDNIMUSTINE; Sterecyt; 29069-24-7; LEO 1031; Prednimustine [USAN:INN]; Prednimustinum [INN-Latin]; Prednimustina [INN-Spanish]; C35H45Cl2NO6; Leo-1031; Chlorambucil prednisolone ester; NSC 134087; UNII-9403SIO2S8; CCRIS 6741; HSDB 6882; Chlorambucil ester of prednisolone; EINECS 249-410-3; NSC-134087; BRN 2826967; CHEBI:82524; 9403SIO2S8; Pregna-1,4-diene-3,20-dione, 21-(4-(4-(bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy)-11,17-dihydroxy-, (11beta)-; Stereocyt; Prednisolone 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate); 11beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate); PrednimustiPrednimustinum; (11beta)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoate; Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-, 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate); NSC-171345; Prednimustine (USAN/INN); SCHEMBL8246; CHEMBL2103751; DTXSID4021183; HFVNWDWLWUCIHC-GUPDPFMOSA-N; ZINC4214173; DB12832; LS-7668; S110; C19512; D05602; Q7239694; 21-[4-[4-[Bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-11,17-dihydroxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-, 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate); Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-, 21-(4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate) (8CI); BRN 2826967
Prednisolone (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione; Prednisolone; 50-24-8; Metacortandralone; Hydroretrocortine; Predonine; Deltacortril; Meticortelone; Deltahydrocortisone; Prenolone; Hydroretrocortin; Delta-Cortef; PRDL; Deltacortenol; Hydrodeltalone; Hydrodeltisone; Codelcortone; Cortalone; Cotogesic; Decaprednil; Delcortol; Deltisilone; Dicortol; Donisolone; Dydeltrone; Erbacort; Erbasona; Estilsona; Fernisolone; Hydeltra; Hydeltrone; Lentosone; Paracortol; Paracotol; Precortancyl; Precortilon; Precortisyl; Prednelan; Prednicen; Predniliderm; Predonin; Rolisone; Scherisolon; Sterolone; Cordrol; Prednis; Prelone; Steran; Ulacort; Fernisolone P; Hostacortin H; Ultracorten H; Ultracortene-H; Delta-stab; Predne-Dome; Decortin H; CO-Hydeltra; Eazolin D; Meti-Derm; Di-adreson F; Delta F; Derpo PD; 1-Dehydrohydrocortisone; Solone; Delta-Ef-Cortelan; Predniretard; delta(1)-Hydrocortisone; delta(1)-Dehydrocortisol; Fernisolone-P; Dexa-Cortidelt hostacortin H; 1,2-Dehydrohydrocortisone; Prednisolona; Prednisolonum; Prednisolonum [INN-Latin]; Prednisolona [INN-Spanish]; delta(1)-Cortisol; Ultracortene-hydrogen; 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione; (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione; delta(sup 1)-Cortisol; UNII-9PHQ9Y1OLM; delta(sup 1)-Hydrocortisone; 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol; 11beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; CCRIS 980; delta(sup 1)-Dehydrocortisol; K 1557; 3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene; Delta(1)-dehydrohydrocortisone; Prednisolone [INN:BAN:JAN]; .DELTA.1-Cortisol; HSDB 3385; delta(sup 1)-Dehydrohydrocortisone; NSC 9120; EINECS 200-021-7; .DELTA.1-Hydrocortisone; 9PHQ9Y1OLM; .DELTA.1-Dehydrocortisol; CHEMBL131; BRN 1354103; CHEBI:8378; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; .DELTA.1-Dehydrohydrocortisone; Poly-Pred; .delta.-Cortef; Neo-Delta-Cortef; OIGNJSKKLXVSLS-VWUMJDOOSA-N; .delta.-Stab; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-; NSC-9120; NSC-9900; Prednisolone, 99%; 11-beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; component of Ataraxoid; 1,4-Pregnadien-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-beta,17-alpha,21-triol; Cotolone; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11b)-; DSSTox_CID_1184; component of K-Predne-Dome; DSSTox_RID_75996; DSSTox_GSID_21184; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; Deltasolone; Klismacort; Panafcortelone; Predate; Bubbli-Pred; 1-Dehydrocortisol; Di-Adreson-F; SMR000718761; MLS002638110; Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-; Predisolone Sodium Phosphate; prednisolon; Preflam; Pregna-1,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; CAS-50-24-8; NCGC00094764-01; delta-hydrocortisone; Prestwick_404; delta-dehydrocortisol; DELTA.1-Cortisol; MFCD00003649; Delta-Cortef (TN); T-Pred (Salt/Mix); Prednisolone (anhydrous); Prednisolone, >=99%; Prestwick0_000274; Prestwick1_000274; Prestwick2_000274; Prestwick3_000274; delta-dehydrohydrocortisone; EC 200-021-7; SCHEMBL3233; K-Predne-Dome (Salt/Mix); 11beta,17alpha,21-Trihydroxypregna-1,4-diene-3,20-dione; .DELTA.(sup 1)-Cortisol; BSPBio_000148; 4-08-00-03467 (Beilstein Handbook Reference); MLS001304083; MLS002154250; MLS002207037; MLS002548883; SPBio_002367; BPBio1_000164; GTPL2866; DTXSID9021184; .DELTA.(sup 1)-Hydrocortisone; BDBM19190; CTK8A1104; Prednisolone (JP17/USP/INN); NSC9120; NSC9900; .DELTA.(sup 1)-Dehydrocortisol; OIGNJSKKLXVSLS-UHFFFAOYSA-N; HMS1568H10; HMS2090J05; HMS2095H10; HMS2230P10; HMS3259E09; HMS3712H10; BCP09053; ZINC3833821; Tox21_111327; Tox21_201673; Tox21_302987; CP0099; LMST02030179; s1737; .DELTA.(sup 1)-Dehydrohydrocortisone; AKOS015894935; Tox21_111327_1; AC-1773; CCG-220274; CS-2249; DB00860; LS-7669; NC00473; NCGC00179649-01; NCGC00179649-02; NCGC00179649-03; NCGC00179649-04; NCGC00179649-06; NCGC00256577-01; NCGC00259222-01; AS-13665; HY-17463; P0637; ST24049031; EN300-53017; 5948-EP0930075A1; 5948-EP2272832A1; 5948-EP2277565A2; 5948-EP2277566A2; 5948-EP2277567A1; 5948-EP2277568A2; 5948-EP2277569A2; 5948-EP2277570A2; 5948-EP2277861A1; 5948-EP2277865A1; 5948-EP2281815A1; 5948-EP2292280A1; 5948-EP2295426A1; 5948-EP2295427A1; 5948-EP2298778A1; 5948-EP2301933A1; 5948-EP2305219A1; 5948-EP2305248A1; 5948-EP2305663A1; 5948-EP2308562A2; 5948-EP2308880A1; 5948-EP2311827A1; 5948-EP2314585A1; 5948-EP2314590A1; 5948-EP2316832A1; 5948-EP2316833A1; 5948-EP2371811A2; C07369; D00472; J10078; Prednisolone, VETRANAL(TM), analytical standard; 003P649; SR-01000837502; Q-201616; SR-01000837502-2; 11b,17,21-Trihydroxypregna-1,4-diene-3,20-dione; BRD-K98039984-001-03-0; BRD-K98039984-001-06-3; Q11426176; 11beta,17,21-trihydroxy-1,4-pregnadiene-3,20-dione; delta-1-Cortisol; Prednicarbate EP Imp A; Supercortisol; Prednisolone, British Pharmacopoeia (BP) Assay Standard; Z1245633279; 11-.beta.,17,21-Trihydroxypregna-1,4-diene-3,20-dione; 11beta,17alpha,21-Trihydroxy-1,4-pregnadiene-3,20-dione; 1,4-Pregnadien-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-.beta.,17-.alpha.,21-triol; Prednisolone, European Pharmacopoeia (EP) Reference Standard; Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-; Pregna-1,4-diene-3,20-dione, 11.beta.,17,21-trihydroxy-; 11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, (11.beta.)-; 11-.beta.,17-.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione; 11-.beta.,17-.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; 11.beta.,17.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; Prednisolone, United States Pharmacopeia (USP) Reference Standard; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy- (8CI); Prednisolone for peak identification, European Pharmacopoeia (EP) Reference Standard; Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard; Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0(2),.0(1)(1),(1)]heptadeca-3,6-dien-5-one; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0; {2,7}.0; {11,15}]heptadeca-3,6-dien-5-one; Prednisolone solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; Prednisolone; delta F
Prednisone
Pregnenolone (3beta)-3-Hydroxy-pregn-5-en-20-one; Pregnenolone; Arthenolone
Primidone 5-Ethyldihydro-5-phenyl-4,6(1H,5H)-pyrimidinedione; primidone; 125-33-7; Primaclone; Mysoline; 2-Deoxyphenobarbital; Lepimidin; Liskantin; Mylepsinum; Lepsiral; Misodine; Mizodin; Mylepsin; Neurosyn; Sertan; 2-Desoxyphenobarbital; Hexadiona; Majsolin; Milepsin; Misolyne; Prilepsin; Primakton; Primidon; Primoline; Prysoline; Midone; Mizolin; Mysedon; Cyral; Medi-Pets; Primacone; Desoxyphenobarbitone; Pyrimidone Medi-pets; Resimatil; Primacione; Primidona; Primidonum; Roe 101; 5-Phenyl-5-ethyl-hexahydropyrimidine-4,6-dione; 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-; 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione; NCI-C56360; Primidone (primaclone); 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione; Primidonum [INN-Latin]; Primidona [INN-Spanish]; 5-ethyl-5-phenyldihydropyrimidine-4,6(1H,5H)-dione; Hexamidine (the antispasmodic); 5-Ethyldihydro-5-phenyl-4,6(1H,5H)-pyrimidinedione; 5-Ethylhexahydro-4,6-dioxo-5-phenylpyrimidine; 5-Ethylhexahydro-5-phenylpyrimidine-4,6-dione; CCRIS 54; NSC 41701; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion; UNII-13AFD7670Q; CHEBI:8412; HSDB 3169; EINECS 204-737-0; 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6); BRN 0218034; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion [German]; 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6) [German]; MLS000028593; DQMZLTXERSFNPB-UHFFFAOYSA-N; 13AFD7670Q; Desoxyphenobarbital; NSC-41701; NCGC00015834-11; CAS-125-33-7; Myidone; SMR000058501; DSSTox_CID_3510; DSSTox_RID_77058; DSSTox_GSID_23510; 5-ethyldihydro-5-phenyl-4,6[1H,5H]-pyrimidinedione; Mysoline (TN); Primidone [USAN:INN:BAN:JAN]; SR-01000003162; 5-ethyl-5-phenyl-1,2,3,5-tetrahydropyrimidine-4,6-dione; Hexamidine(the antispasmodic); Primidone [USP:INN:BAN:JAN]; Primidone(Mysoline); Primidone (Mysoline); Spectrum_000832; Tocris-0830; Pyrimidone 'Medi-pets'; Opera_ID_1083; Prestwick0_000933; Prestwick1_000933; Prestwick2_000933; Prestwick3_000933; Spectrum2_001293; Spectrum3_000553; Spectrum4_000485; Spectrum5_001144; Lopac-P-7295; Mysoline; Neurosyn; Mylepsin; Biomol-NT_000261; CHEMBL856; P 7295; Pyrimidone ''Medi-pets''; 5-ethylhe xahydro-4,6-dioxo-5-phenylpyrimidine; Lopac0_001021; SCHEMBL34221; BSPBio_000866; BSPBio_002225; KBioGR_000969; KBioSS_001312; 5-24-08-00102 (Beilstein Handbook Reference); MLS001055411; MLS001074125; BIDD:GT0319; DivK1c_000324; Primidone, analytical standard; SPECTRUM1500501; SPBio_001325; SPBio_003035; Primidone (JP17/USP/INN); 5-Ethyl-5-phenyldihydro-4,6(1H,5H)-pyrimidinedione; BPBio1_000859; BPBio1_000954; GTPL5338; ZINC1979; hexamidine (the antispasmodic); DTXSID7023510; CTK8B3224; HMS501A06; KBio1_000324; KBio2_001312; KBio2_003880; KBio2_006448; KBio3_001725; WLN: T6MV DVMTJ C2 CR; NINDS_000324; HMS1570L08; HMS1920J20; HMS2092A21; HMS2097L08; HMS2236G03; HMS3259K04; HMS3263M03; HMS3266H18; HMS3369J12; HMS3411N13; HMS3655L05; HMS3675N13; HMS3714L08; LS-48; Pharmakon1600-01500501; HY-B0339; KS-00000XM8; NSC41701; Tox21_110238; Tox21_201948; Tox21_303194; Tox21_501021; ANW-42020; BDBM50248152; BG0404; CCG-39231; NSC757291; s1965; SBB017254; AKOS003368409; Tox21_110238_1; API0003929; CS-2381; DB00794; KS-5217; LP01021; MCULE-2519004832; NC00532; NSC-757291; SDCCGSBI-0050994.P005; IDI1_000324; SMP1_000135; NCGC00015834-01; NCGC00015834-02; NCGC00015834-03; NCGC00015834-04; NCGC00015834-05; NCGC00015834-06; NCGC00015834-07; NCGC00015834-08; NCGC00015834-09; NCGC00015834-10; NCGC00015834-12; NCGC00015834-13; NCGC00015834-14; NCGC00015834-15; NCGC00015834-16; NCGC00015834-17; NCGC00015834-19; NCGC00016377-01; NCGC00023254-02; NCGC00023254-04; NCGC00023254-05; NCGC00023254-06; NCGC00023254-07; NCGC00023254-08; NCGC00023254-09; NCGC00023254-10; NCGC00257146-01; NCGC00259497-01; NCGC00261706-01; AK546499; CC-33920; CPD000058501; H808; SAM002554925; SC-18998; ST076725; SBI-0050994.P004; AB0013274; AB2000396; TR-003816; AB00052079; EU-0101021; FT-0603328; P1906; SW196576-3; 5-Ethyldihydro-5-phenyl-4,5H)-pyrimidinedione; C07371; D00474; K-1838; AB00052079-14; AB00052079_15; AB00052079_16; 125P337; 4,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-; A805374; Q420383; J-005215; SR-01000003162-2; SR-01000003162-4; SR-01000003162-5; SR-01000003162-8; BRD-K32247306-001-05-4; BRD-K32247306-001-17-9; 5-Ethyl-5-phenyldihydro-4,6(1H,5H)-pyrimidinedione #; Primidone, European Pharmacopoeia (EP) Reference Standard; Primidone, United States Pharmacopeia (USP) Reference Standard; Primidone for peak identification, European Pharmacopoeia (EP) Reference Standard; Primidone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Primidone; 5-24-08-00102 (Beilstein Handbook Reference)
Pro-Air rel-8-Hydroxy-5-[(1R,2S)-1-hydroxy-2-[(1-methylethyl)amino]butyl]-2(1H)-quinolinone; Procaterol; EINECS 276-590-0
Probenecid 4-[(Dipropylamino)sulfonyl]benzoic acid; Probenecid; 4-11-00-00691 (Beilstein Handbook Reference)
Procaine penicillin G (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid compd. with 2-(diethylamino)ethyl 4-aminobenzoate (1:1); Procaine penicillin; Benzilpenillina procainica [DCIT]
Procarbazine N-(1-Methylethyl)-4-[(2-methylhydrazinyl)methyl]benzamide; Procarbazine; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-
Proflavine 3,6-Acridinediamine; Proflavine; Proflavin; acridine-3,6-diamine; 3,6-ACRIDINEDIAMINE; 3,6-Diaminoacridine; 92-62-6; Isoflav base; Proflavina; Proflavinum; 2,8-Diaminoacridinium; 3,6-Diaminoacridinium; Proflavine [INN]; Proflavine hemisulfate; 3,7-Diamino-5-azaanthracene; Proflavinum [INN-Latin]; Proflavina [INN-Spanish]; 2,8-Diaminoacridine; 2,8-Diaminoacridine (European); UNII-CY3RNB3K4T; Acridine, 3,6-diamino-; CCRIS 1244; HSDB 7071; EINECS 202-172-4; CY3RNB3K4T; BRN 0166050; AI3-52128; CHEBI:8452; WDVSHHCDHLJJJR-UHFFFAOYSA-N; C13H11N3; 1811-28-5; Profura; Progarmed; 531-73-7; PRL; NCGC00166245-01; 1bcu; 1qvt; 1qvu; 3,6-Acridinediamine hydrochloride; 3,6-diaminoacridin; 3,6-Diaminoacridine hemisulfate salt; NCIMech_000209; SCHEMBL27386; 5-22-11-00322 (Beilstein Handbook Reference); AE-562/12222295; CHEMBL55400; Acridine-3,6-diamine (HCl); SCHEMBL8149677; DTXSID9043776; BDBM12590; CTK3I6712; WDVSHHCDHLJJJR-UHFFFAOYSA-; 2v57; Proflavine hemisulfate salt hydrate; 3,6-diamino acridine hydrochloride; ALBB-024962; ZINC3775644; ZX-AN023476; BBL002984; MFCD00005030; MFCD00149650; SBB072167; STK380650; AKOS005449844; API0008968; DB01123; MCULE-9362278105; NCGC00166245-02; LS-14311; NCI60_004643; NCI60_004767; NCI60_032077; SC-48125; ST012247; CS-0013756; R1243; S5776; C11181; AB00375967-03; AB00375967_04; (6-aminoacridin-3-yl)amine; sulfuric acid; hydrate; Q420454; SR-01000883943; SR-01000883943-1; UNII-1T3A50395T component WDVSHHCDHLJJJR-UHFFFAOYSA-N; InChI=1/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2; Proflavine; 5-22-11-00322 (Beilstein Handbook Reference)
Proline L-Proline; L-proline; 147-85-3; proline; L-(-)-Proline; H-Pro-OH; (S)-Pyrrolidine-2-carboxylic acid; (2S)-pyrrolidine-2-carboxylic acid; 2-pyrrolidinecarboxylic acid; (-)-Proline; (-)-(S)-Proline; (S)-2-Pyrrolidinecarboxylic acid; Prolinum; (-)-2-Pyrrolidinecarboxylic acid; L-Pyrrolidine-2-carboxylic acid; prolina; (S)-Proline; L-alpha-Pyrrolidinecarboxylic acid; L-Prolin; Prolinum [Latin]; Prolina [Spanish]; Proline, L-; Proline (VAN); (S)-2-Carboxypyrrolidine; Proline [USAN:INN]; (L)-PROLINE; (S)-(-)-Proline; 2-Pyrrolidinecarboxylic acid, (S)-; FEMA Number 3319; CB 1707; PRO (IUPAC abbreviation); FEMA No. 3319; HSDB 1210; UNII-9DLQ4CIU6V; AI3-26710; EINECS 205-702-2; MFCD00064318; NSC 46703; 9DLQ4CIU6V; CHEMBL54922; CHEBI:17203; ONIBWKKTOPOVIA-BYPYZUCNSA-N; Proline (L-Proline); Prolin; Carboxypyrrolidine; L-(2,3-3H)Proline; Proline (USP); L-Proline, labeled with carbon-14; 2-Pyrrolidinecarboxylate; racemic proline; rac-proline; s-proline; NSC-97923; 3h-l-proline; L-Proline; (s)-prolin; femanumber3319; H-Pro; (2S)-proline; Pro-OH; L-Proline,(S); L-Pro-OH; (-)-Proline (S)-2-Carboxypyrrolidine; L-Proline (JP17); 2-Pyrrolidinecarboxylicacid; bmse000047; bmse000947; EC 205-702-2; (2S)-2-carboxypyrrolidine; SCHEMBL7792; H-Pro-2-Chlorotrityl Resin; (S)-2-Pyrralidinecarboxylate; (S)-2-Pyrrolidinecarboxylate; KSC176C3H; (-)-2-Pyrrolidinecarboxylate; L(-)-Proline, 99+%; (s)-2-pyrrolidinecarboxylicaci; (S)-(-)-PROLIN; GTPL3314; (s)-2-pyrrolidinecarboxylicacid; DTXSID5044021; CTK0H6133; L-Proline, 99%, FCC, FG; (S)-2-Pyrralidinecarboxylic acid; pyrrolidin-2-(S)-carboxylic acid; Pharmakon1600-01301007; ZINC895360; (2S)-Pyrrolidin-2-carbonsalphaure; pyrrolidine-2-(S)-carboxylic acid; BCP25292; HY-Y0252; (S) -pyrrolidine-2-carboxylic acid; L-Proline, >=99.0% (NT); (S)-(-)-Pyrrolidine-2-carboxylate; ANW-49297; BDBM50000100; NCGC00014017; NSC760114; s5629; AKOS010372120; AKOS015856025; CCG-214709; CS-W019861; DB00172; LS-2381; MCULE-8415049837; NSC-760114; RTC-064025; (S)-(-)-Pyrrolidine-2-carboxylic acid; NCGC00014017-02; NCGC00014017-03; NCGC00097126-01; 37159-97-0; 4305-67-3; AC-11190; AS-10803; BR-44539; SC-09806; L-Proline, BioUltra, >=99.5% (NT); AB0064943; AB1002323; DB-029981; L-Proline, SAJ special grade, >=99.0%; TC-064025; AM20080359; BB 0242381; FT-0628004; L-Proline, Vetec(TM), 98.5-101.5%; P0481; ST24033226; L-Proline, Vetec(TM) reagent grade, >=99%; C00148; D00035; L-Proline, ReagentPlus(R), >=99% (HPLC); M-5893; M02947; 27675-EP2298767A1; 27675-EP2314587A1; 65150-EP2272510A1; 65150-EP2277898A2; 65150-EP2284159A1; 65150-EP2287165A2; 65150-EP2287166A2; 65150-EP2289892A1; 65150-EP2292620A2; 65150-EP2292630A1; 65150-EP2295439A1; 65150-EP2305687A1; 65150-EP2308812A2; 125850-EP2272510A1; 125850-EP2295422A2; 147P853; Q-201327; L-Proline, certified reference material, TraceCERT(R); Q20035886; A01B5B63-CC3D-4796-A7B4-C2DE26A6FA93; F0001-2348; Proline, European Pharmacopoeia (EP) Reference Standard; Z1245635771; UNII-0O72R8RF8A component ONIBWKKTOPOVIA-BYPYZUCNSA-N; UNII-DCS9E77JPQ component ONIBWKKTOPOVIA-BYPYZUCNSA-N; L-Proline, United States Pharmacopeia (USP) Reference Standard; L-Proline, Pharmaceutical Secondary Standard; Certified Reference Material; L-Proline, from non-animal source, meets EP, USP testing specifications, suitable for cell culture; L-Proline, PharmaGrade, Ajinomoto, EP, JP, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture; Proline; AI3-26710
Promazine N,N-Dimethyl-10H-phenothiazine-10-propanamine; Promazine; A 145
Propionamide PROPIONAMIDE; Propanamide; 79-05-0; Propionic amide; Propylamide; Propanimidic acid; Propionic acid amide; Propionimidic acid; Amid kyseliny propionove; Propanimidic acid (VAN); Propionimidic acid (VAN); UNII-QK07G0HP47; Propionamide, 97%; Amid kyseliny propionove [Czech]; EINECS 201-172-1; MFCD00008039; NSC 38708; BRN 0969258; propioamide; AI3-21217; QK07G0HP47; CHEBI:45422; QLNJFJADRCOGBJ-UHFFFAOYSA-N; n-propionic amide; ACMC-1BJ8Y; WLN: ZV2; 4-02-00-00725 (Beilstein Handbook Reference); KSC378E2R; CHEMBL1235716; DTXSID3058820; CTK2H8228; KS-00000GZD; NSC38708; STR08476; ZINC1670847; ANW-37252; NSC-38708; STL363023; AKOS005177582; CS-W016688; DB04161; MCULE-3730796130; NE10546; RTR-025203; TRA0037652; AK308443; S216; SC-18213; SY048276; DB-031910; LS-123996; TR-025203; FT-0631349; P0499; EN300-15614; Propionamide, Vetec(TM) reagent grade, 97%; 32530-EP2301933A1; 32530-EP2311827A1; 97843-EP2305685A1; 97843-EP2305686A1; 101962-EP2275469A1; 101962-EP2287940A1; 101962-EP2289965A1; 101962-EP2298828A1; 101962-EP2301983A1; J-524060; Q3082378; Z33546482; F0001-2069; InChI=1/C3H7NO/c1-2-3(4)5/h2H2,1H3,(H2,4,5; 4-02-00-00725 (Beilstein Handbook Reference)
Propofol 2,6-Bis(1-methylethyl)phenol; propofol; 2,6-DIISOPROPYLPHENOL; 2078-54-8; Diprivan; Disoprofol; Disoprivan; Diisopropylphenol; 2,6-Bis(1-methylethyl)phenol; Fresofol; Ampofol; Rapinovet; Phenol, 2,6-bis(1-methylethyl)-; Propofolum; Recofol; Ivofol; Propofol-Lipuro; Pofol; ICI 35868; 2,6-di(propan-2-yl)phenol; Propofolum [Latin]; Diprifusor; Diprofol; Propovan; Phenol, 2,6-diisopropyl-; 2,6-Diisopropyl phenol; Diprivan 10; Diprivan Injectable emulsion; 2,6-bis(propan-2-yl)phenol; UNII-YI7VU623SF; NSC 5105; ICI-35868; CCRIS 9000; HSDB 7123; C12H18O; 2,6-diisopropyl-phenol; EINECS 218-206-6; 2,6-bis(Isopropyl)phenol; CHEMBL526; BRN 1866484; YI7VU623SF; AI3-26295; CHEBI:44915; NSC5105; OLBCVFGFOZPWHH-UHFFFAOYSA-N; NSC-5105; MFCD00008885; NCGC00015389-08; Aquafol; CAS-2078-54-8; DSSTox_CID_3523; DSSTox_RID_77063; DSSTox_GSID_23523; 2,6 Diisopropylphenol; Dipravan; Propoven; Aquafo; Propofol IDD-D; Diprivan (TN); Propofol [USAN:INN:BAN]; SMR000059151; 2, 6-Diisopropylphenol; SR-01000075468; Propofol (JAN/USAN/INN); DDS-04F; ghl.PD_Mitscher_leg0.558; Propofol [USAN:USP:INN:BAN]; ICI35,868; Propofol (Diprivan); ICI 35,868; ICI-35,868; ZD-0859; Phenol,6-diisopropyl-; ACMC-1CPLW; Prestwick0_000931; Prestwick1_000931; Prestwick2_000931; Prestwick3_000931; 2,6-di isopropyl phenol; Biomol-NT_000248; Lopac-D126608; Diisopropylphenol (Related); 2,6-bis(methylethyl)phenol; Lopac0_000437; SCHEMBL36245; BSPBio_000862; 4-06-00-03435 (Beilstein Handbook Reference); KSC490K5P; MLS001066348; MLS001335999; MLS002454360; BIDD:GT0436; SPECTRUM1505022; SPBio_003031; 2,6-Diisopropylphenol, 97%; BPBio1_000950; BPBio1_000969; GTPL5464; Phenol,6-bis(1-methylethyl)-; DTXSID6023523; CTK3J0557; Propofol 1.0 mg/ml in Methanol; 2,6-Diisopropylphenol, >=97%; 3f33; 3p50; HMS1570L04; HMS2089O21; HMS2094E17; HMS2097L04; HMS2231E16; HMS3259E03; HMS3261G16; HMS3369I16; HMS3714L04; Pharmakon1600-01505022; ZINC968303; BCP02920; KS-00000MQ0; Tox21_110134; Tox21_201371; Tox21_303225; Tox21_500437; ANW-24224; BDBM50058046; CP0141; LS-996; NSC758909; Phenol, 2, 6-bis(1-methylethyl)-; AKOS009159417; Tox21_110134_1; AC-2038; AM90311; CCG-204529; CS-W020057; DB00818; ICI 35-868; LP00437; MCULE-1903292305; NC00449; NSC-758909; RTR-009757; SDCCGSBI-0050422.P002; TRA0038441; VZ22957; 2,6-DIISOPROPYLPHENOL; PROPOFOL; MLS-0318084; NCGC00015389-01; NCGC00015389-02; NCGC00015389-03; NCGC00015389-04; NCGC00015389-05; NCGC00015389-06; NCGC00015389-07; NCGC00015389-09; NCGC00015389-10; NCGC00015389-11; NCGC00015389-14; NCGC00091538-01; NCGC00091538-02; NCGC00091538-03; NCGC00091538-04; NCGC00091538-05; NCGC00091538-06; NCGC00257228-01; NCGC00260670-01; NCGC00261122-01; AS-13299; CPD000059151; H835; SAM002264610; SC-18796; SY013479; 2,6-Diisopropylphenol, analytical standard; BCP0726000298; MLS-0318084.P017; ST2415947; TR-009757; AB00513968; D0617; EU-0100437; FT-0610672; ST50405911; C07523; D00549; AB00513968-07; AB00513968_08; A814898; D126608; Q422740; Q-201631; SR-01000075468-1; SR-01000075468-4; SR-01000075468-6; BRD-K82255054-001-03-5; BRD-K82255054-001-08-4; Propofol, British Pharmacopoeia (BP) Reference Standard; Propofol, European Pharmacopoeia (EP) Reference Standard; Z1245735300; Propofol, United States Pharmacopeia (USP) Reference Standard; Propofol, Pharmaceutical Secondary Standard; Certified Reference Material; InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H; Propofol for peak identification, European Pharmacopoeia (EP) Reference Standard; Propofol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Propofol; 4-06-00-03435 (Beilstein Handbook Reference)
Propranolol 1-[(1-Methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol; Propranolol; Betalong
Propranolol hydrochloride 1-[(1-Methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol hydrochloride (1:1); Propranolol hydrochloride; I 2065
Propyl acetate Acetic acid, Propyl ester; Acetic acid, propyl ester; 4-02-00-00138 (Beilstein Handbook Reference)
Propyl benzoate Benzoic acid, Propyl ester; Propyl benzoate; AI3-01973
Propyl gallate 3,4,5-Trihydroxybenzoic acid propyl ester; Benzoic acid, 3,4,5-trihydroxy-, propyl ester; AI3-17136
Propylene glycol (veterinary drug) 1,2 Propanediol; 1,2-Propanediol; Glycol, Propylene; Monohydrate, Propylene Glycol; Propan-1,2-Diol; Propylene Glycol; Propylene Glycol Monohydrate; Propylene Glycol Sodium Salt; Propylene Glycol, (+-)-Isomer; Propylene; Glycol, (R)-Isomer; Propylene Glycol, (S)-Isomer
Protirelin 5-Oxo-L-prolyl-L-histidyl-L-prolinamide; protirelin; Thyroliberin; 24305-27-9; Lopremone; Rifathyroin; Synthetic TRH; Thyrotropin-releasing hormone; Thypinone; TSH-releasing factor; TSH-releasing hormone; TRH; Thyrotropin releasing hormone; Thyrotropic-releasing factor; Thyrotropic releasing hormone; 5-Oxo-L-prolyl-L-histidyl-L-prolinamide; Abbott 38579; Thyrotropin-releasing factor; ABBOTT-38579; L-Pyroglutamyl-L-histidyl-L-prolineamide; UNII-5Y5F15120W; THYREL TRH; ProtireliCHEBI:35940; C16H22N6O4; Synthetic tsh-releasing factor; Synthetic tsh-releasing hormone; 5Y5F15120W; NCGC00160616-01; L-Pyroglutamyl-L-histidinyl-L-prolinamide; FDA 1725; Protirelin acetate; Thyroid releasing hormone; Protireline [INN-French]; Protirelinum [INN-Latin]; Protirelina [INN-Spanish]; L-Pyroglutamyl-L-histidyl-L-prolinamide; Thyrothropin relasing hormone; A-38579; Ro 8-6270/9; CCRIS 2593; L-Prolinamide, 5-oxo-L-prolyl-L-histidyl-; Protireline; Protirelinum; EINECS 246-143-4; Thyrefact; trh-sr; Synthetic TRF; Relefact-TRH; Protirelin [USAN:INN:BAN:JAN]; Stimu-TSH; Thyrotropin-releasing factor (pig); TRF; PR 546; PR-546; Relefact TRH (TN); PyroGlu-His-prolinamide; TSH-RF; DSSTox_CID_3533; Thyrotropin-ReleasingHormone; CHEMBL1472; DSSTox_RID_77067; DSSTox_GSID_23533; SCHEMBL33419; Thyrotrophin releasing hormone; 117217-40-0; GTPL2139; pyroglutamyl-histidyl-prolinamide; DTXSID0023533; Protirelin (JP17/USAN/INN); SCHEMBL19825647; KS-00002WUW; XNSAINXGIQZQOO-SRVKXCTJSA-N; HY-P0002; Thyrotropic hormone-releasing factor; ZINC4096261; Synthetic thyrotopin releasing factor; Thyrotropic hormone-releasing hormone; Tox21_111939; BDBM50072394; CP-236; s4680; Synthetic thyrotropin-releasing factor; Thyrotrophic hormone releasing hormone; AKOS015994636; Synthetic thyrotropin-releasing hormone; CS-7080; DB09421; HS-2023; L-Pyroglutamyl-L-histidyl-L-proline amide; AB0011512; CAS-24305-27-9; Thyroid-stimulating hormone-releasing factor; FT-0638410; FT-0639185; C03958; D00176; Prolinamide, 5-oxo-L-prolyl-L-histidyl-, L-; (Pyro)-L-glutamic acid-L-histidine-L-proline-NH2; 305T279; Q24726011; Thyrotropin releasing hormone, >=98% (HPLC), powder; Prolinamide, 1-[N-(5-oxo-L-prolyl)-L-histidyl]-, L-; Protirelin, European Pharmacopoeia (EP) Reference Standard; Thyrotropin releasing hormone, powder, gamma-irradiated, cell culture tested; Thyroliberin; Lopremone; Synthetic TRH; Thyrotropin-releasing hormone; Rifathyroin; (2S)-N-[(1S)-2-[(2S)-2-carbamoylpyrrolidino]-1-(1H-imidazol-5-ylmethyl)-2-keto-ethyl]-5-keto-pyrrolidine-2-carboxamide; (2S)-N-[(2S)-1-[(2S)-2-aminocarbonylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxidanylidene-propan-2-yl]-5-oxidanylidene-pyrrolidine-2-carboxamide; (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide; (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide; (S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)-5-oxopyrrolidine-2-carboxamide; (S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl)-5-oxopyrrolidine-2-carboxamide; 1-(3-(1H-Imidazol-5-yl)-2-([(5-oxo-2-pyrrolidinyl)carbonyl]amino)propanoyl)-2-pyrrolidinecarboxamide #; 1-[3-(1H-4-imidazolyl)-2-(5-oxotetrahydro-1H-2-pyrrolylcarboxamido)propanoyl]tetrahydro-1H-2-pyrrolecarboxamide; 2-Pyrrolidinecarboxamide, N-[1-[(2-carbamoyl-1-pyrrolidinyl)carbonyl]-2-imidazol-4-ylethyl]-5-oxo-,; 2-Pyrrolidinecarboxamide, N-[1-[(2-Carbamoyl-1-pyrrolidinyl)carbonyl]-2-imidazol-4-ylethyl]-5-oxo-, (S,S,S)-; Protirelin; CCRIS 2593
Protocatehuic acid 3,4-Dihydroxybenzoic acid; Protocatechuic acid; 4-10-00-01459 (Beilstein Handbook Reference)
Protriptyline N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; protriptyline; Amimetilina; Protryptyline; Triptil; 438-60-8; Vivactil; Protriptyline [INN:BAN]; Protriptylinum [INN-Latin]; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene; Protriptilina [INN-Spanish]; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; Maximed; Triptyl; Vivactyl; UNII-4NDU154T12; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; HSDB 3391; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; EINECS 207-119-9; Triptil hydrochloride; CHEMBL668; Normethyl EX4442; BRN 2217411; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo(a,d)cycloheptene-5-propanamine, N-methyl-; 5H-Dibenzo[a,d]cycloheptene-5-propanamine, N-methyl-; CHEBI:8597; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; BWPIARFWQZKAIA-UHFFFAOYSA-N; 4NDU154T12; Concordin; 5H-Dibenzo(a,d)cycloheptene-5-propylamine, N-methyl-; Protriptilina; Protriptylinum; Protriptyline (INN); MK-240; NSC169912; NCGC00015851-02; CAS-1225-55-4; 5H-Dibenzo[a,d]cycloheptene-5-propylamine, N-methyl-; Vivactil (Salt/Mix); Concordin (Salt/Mix); Prestwick0_000930; Prestwick1_000930; Prestwick2_000930; Prestwick3_000930; Lopac-P-8813; BIDD:PXR0157; Lopac0_000974; SCHEMBL34267; BSPBio_000840; SPBio_003019; BPBio1_000924; GTPL7285; DTXSID0023535; PROTRYPTYLINE HYDROCHLORIDE; ZINC1530764; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; ACM438608; BDBM50176062; MK 240; PDSP1_001390; PDSP2_001374; AKOS015962184; CCG-205054; DB00344; MCULE-6023848462; SDCCGSBI-0050947.P003; NCGC00015851-01; NCGC00015851-03; NCGC00015851-04; NCGC00015851-05; NCGC00015851-06; NCGC00015851-07; NCGC00024439-03; AC-15971; LS-60771; SBI-0050947.P002; AB00489964; C07408; D08447; AB00489964_10; L000913; Q408432; BRD-K42098891-003-03-1; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine #; 3-(11H-dibenzo[[?],[?]][7]annulen-11-yl)-N-methyl-propan-1-amine; 3-(11H-dibenzo[1,2-a:1',2'-e][7]annulen-11-yl)-N-methylpropan-1-amine; methyl(3-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-yl}propyl)amine; Protriptyline; Amimetilina
Prussian blue (OC-6-11)-Hexakis(cyano-kappaC)ferrate(4-), Iron(3+) (3:4); Ferrate(4-), hexakis(cyano-C)-, iron(3+) (3:4); EINECS 237-875-5
Pseudoephedrine (alphaS)-alpha-[(1S)-1-(Methylamino)ethyl]benzenemethanol; (+)-Pseudoephedrine; Benzenemethanol, alpha-(1-(methylamino)ethyl)-, (S-(R*,R*))-